CRS Appoints Dr. Elisabeth Lackner as New CEO to Spearhead Strategic Growth

CRS Clinical Research Services, a leading early-phase Contract Research Organization (CRO), announced the appointment of Dr. Elisabeth Lackner as its new Chief Executive Officer (CEO), effective March 15, 2024. Tasked with steering the company’s strategic direction, Dr. Lackner's focus will be on internationalization and enhancing the quality, innovation, and client satisfaction of CRS's services.

With over two decades of experience in the healthcare sector, Dr. Lackner's extensive background includes roles such as Chief Scientific Officer at Element Materials and Managing Director at Vineta. Her achievements include leading significant mergers and international expansions, demonstrating her capability to transform companies into globally recognized entities.

Daniel Sehrt, a shareholder representative of CRS, expressed confidence in Dr. Lackner's ability to navigate the company through the complexities of today’s fast-evolving clinical research landscape. Her appointment is seen as timely, aligning with the organization's growth strategy and the industry's increasing demand for technological advancement, disease expertise, and patient-centricity.